Accreditation/Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Portola Pharmaceuticals, Inc.

Medical Crossfire®: Moving the Field Forward with DOAC Reversal Agents

Release Date: July 31, 2019
Expiration Date: July 31, 2020
Media: Internet - based

Activity Overview

The field of direct oral anticoagulant (DOAC) reversal agents is relatively new. A known adverse event among all anticoagulation therapies is increased risk of bleeding following therapy. Any bleeding patient on an anticoagulant should be risk-stratified based on hemodynamic instability, source of bleeding, and degree of blood loss. Many questions surround the implementation of reversal agents into practice including which clinician patients should seek when bleeding occurs. This activity, titled “Medical Crossfire®: Moving the Field Forward with DOAC Reversal Agents,” will cover the clinical need for reversal agents, current guidelines on reversal therapies, and the role of clinicians across several disciplines and the clinical implications within each therapeutic area.

Benefits of Participating

  • Gain insights into the importance of addressing bleeding risks following anticoagulant therapy and into the mechanisms of action of DOAC agents
  • Improve competence regarding the integration of novel therapies into the management of thromboembolic disease and the use of reversal agents following bleeding episodes
  • Increase awareness of multidisciplinary strategies in the care of patients on anticoagulation therapy

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Portola Pharmaceuticals, Inc.

Instructions for This Activity and Receiving Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review video files/content until you finish the presentation.
  • At the end of the activity, educational content/video files will be available for your reference.
  • In order to receive a CME/CE certificate, you must complete the activity.
  • Complete the Posttest and pass with a score of 70% or higher, complete the Evaluation, and then click on “Request for Credit.” You may immediately download a CME/CE certificate upon completion of these steps.


Target Audience

This online educational activity is directed toward emergency medicine physicians, nurses, hospitalists, cardiologists, neurologists, hematologists, and other healthcare professionals interested in the treatment of patients in need of DOAC reversals.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Evaluate the bleeding risk of patients on DOAC therapy and the mechanisms of action of different agents
  • Assess the efficacy and safety of reversal agents for DOAC therapy
  • Develop strategies to bridge gaps in management of patients on DOAC therapy

Faculty, Staff, and Planners’ Disclosures

Faculty

Charles V. Pollack Jr
Charles V. Pollack Jr, MD, MA, FACEP, FAAEM, FAHA, FACC, FESC
Adjunct Professor of Emergency Medicine
Lewis Katz School of Medicine
Temple University
Philadelphia, PA

Disclosures: Grants/Research Support: Boehringer Ingelheim, CSL Behring, Daiichi Sankyo, Janssen, Portola Pharma; Consultant: Boehringer Ingelheim, Janssen, Portola Pharma.

Deepak L. Bhatt
Deepak L. Bhatt, MD, MPH
Executive Director of Interventional Cardiovascular Programs
Brigham and Women’s Hospital
Professor of Medicine
Harvard Medical School
Boston, MA

Disclosures: Grants/Research Support: Abbott, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Chiesi, Eisai, Ethicon, Forest Laboratories, Idorsia, Ironwood Pharmaceuticals, Ischemix, Lilly, Medtronic, PhaseBio, Pfizer, Regeneron, Roche, Sanofi-Aventis, Synaptic, The Medicines Company.

Krishna Gundabolu
Krishna Gundabolu, MD, FACP
Associate Professor, Department of Hematology-Oncology
Director of the Thrombosis and Hemostasis Program
University of Nebraska Medical Center
Omaha, NE

Disclosures: Stockholder: Portola Pharmaceuticals.

Edward M. Manno
Edward M. Manno, MD, MS
Vice Chair of Clinical Affairs
Department of Neurology
Northwestern University Feinberg School of Medicine
Director of the Neurological Intensive Care Unit, Northwestern Memorial Hospital
Chicago, IL

Disclosures: Edward Manno has no relevant financial relationships with commercial interests to disclose.

The staff of Physicians' Education Resource®, LLC (PER®), have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME/CE activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only and is not meant to substitute for the independent clinical judgment of a physician or nurse relative to diagnostic or treatment options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members, and do not reflect those of PER® or any of the companies that provided commercial support for this program.


Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
    123
45678910
11121314151617
18192021222324
25262728293031
Filter By